Project Grant R01CA298935
Award Date
5/6/25
Completion Date
4/30/30
Dollars Obligated
$677K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $225,101 to support research aimed at understanding the increased risk of hematological malignancy in sickle cell disease. The research will investigate how oxidative stress and DNA damage in hematopoietic stem and progenitor cells can lead to the development of deleterious mutations and clonal hematopoiesis, which may predispose sickle cell patients to hematological...
This Project Grant award of $134,123.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to enhance the ability to identify and treat pediatric hematopoietic cell transplant (HCT) patients with or at-risk for pulmonary fibrosis (PF). The primary goals are to identify bronchoalveolar lavage fluid (BAL) and blood-based transcriptomic and proteomic signatures that differentiate HCT patients with and without PF, and to...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $135,724.00 in funding to the Regents of the University of Minnesota to conduct a research project titled "Living Beyond Cancer: How Distance Impacts Childhood Cancer Survivorship Care" over the period from August 23, 2024 to August 22, 2027. The project aims to investigate how geographic distance impacts the delivery of survivorship care for childhood cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $433,895.00 to the Sloan-Kettering Institute for Cancer Research to examine the psychosocial, ethical, and clinical implications of incidental medical findings of clonal hematopoiesis (CH) in healthy hematopoietic stem cell (HSC) donors. The award will fund a feasibility study to (1) qualitatively assess the psychosocial impact of receiving information about incidental CH...
This $576,659 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to investigate tumor and host immune signatures associated with disparities in outcomes following GD2 immunotherapy for patients with high-risk neuroblastoma. The primary awardee, Emory University, is collaborating with sub-awardees Dana-Farber Cancer Institute and University of Florida to: Perform tumor-based single cell genomic, proteomic, and...
The University of Alabama at Birmingham received a $661,845 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to study structural racism's impact on the quality of end-of-life care for children with cancer. The 5-year project aims to examine how access to care, patient/family interactions with the healthcare system, and stress influence variations in quality of end-of-life care, develop a predictive model to identify high-risk...
This Project Grant award, totaling $589,591, was provided by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353). The objective of this 5-year study is to determine how social factors may explain poorer survival outcomes for Black and Hispanic patients with Hodgkin lymphoma. The key products and services to be delivered under this award include: Examining differences in the receipt and quality of Hodgkin lymphoma...
This Project Grant award, totaling $1,399,812.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award is focused on conducting research to assess outcomes and late effects in pediatric and adolescent germ cell tumor survivors. The research will be carried out by the Regents of the University of Minnesota, which has a prominent track record in executing federal research contracts and grants across various...
This $1,073,982 National Cancer Institute project grant will fund research at Washington University in University City, Missouri from January 2023 through December 2027 under the Cancer Cause and Prevention Research program (CFDA 93.393). The research aims to document unmet social needs among 300 patient-caregiver dyads where the patient has breast or gynecologic cancer. It will analyze how social needs affect biopsychosocial outcomes for patients and caregivers, including depressive symptoms,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $172,013 to support the research work of a pediatric oncologist at the University of Colorado-Denver over the period of September 19, 2024 to August 31, 2029. The funded research aims to improve outcomes for children with acute lymphoblastic leukemia, particularly those who experience disease relapse, through the incorporation of novel targeted therapies into treatment regimens. The...